Volume-rendered optical coherence tomography (OCT) imaging allows new insight into retinal vascular flow and morphological changes in eyes with macular edema (ME), and the information obtained is the basis for new ideas about the pathogenesis of ME and therapeutic intervention, according to Richard F. Spaide, MD, Vitreous Retina Macula Consultants of New York.
Results from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Researchers have identified a new biomarker they believe can be used as a predictor of vision change in patients with diabetic macular edema, either during the natural history of the disease or after undergoing anti-VEGF therapy. The biomarker is disorganization of the retinal inner layers, or DRIL.
A new class of ophthalmic drug continues to show promise for treating patients with diabetic macular edema (DME).
When it comes to finding new treatments for diabetic macular edema (DME), there is no shortage of promising targets, said Peter A. Campochiaro, MD. He presented an overview of future compounds with various mechanisms of action that may change how clinicians treat DME.
As a physician passionate about treating and helping patients with retinal disease, I continuously seek out and study new treatment modalities. It can be a very scary time for patients when faced with retinal conditions, such as macular degeneration, retinal detachments, and diabetic macular edema (DME).
Results from TIME-2, a phase IIA study, support further development of combination treatment with subcutaneous injection of the Tie2 activator, AKB-9778 (Aerpio Therapeutics), plus intravitreous (IVT) anti-VEGF injection for diabetic macular edema.
Results from a phase I study of KVD001 (KalVista Pharmaceuticals) for the treatment of central involved diabetic macular edema (CIDME) show that this plasma kallikrein inhibitor was well-tolerated, not associated with any ophthalmic or systemic safety signals, and led to fairly long-lasting improvements in visual acuity (VA) and central retinal thickness (CRT) after a single intravitreous injection.